Tonix Pharmaceuticals is a development stage specialty pharmaceutical company, which focuses on the development of pharmaceutical products for the disorders of central nervous system. The Company's lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. Tonix is also developing TNX-601, a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder; and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.
Type | Public | |
Founded | 2007 | |
HQ | New York, NY, US | Map |
Website | tonixpharma.com |
USD | |
---|---|
Net income (Q2, 2020) | (14.2m) |
EBIT (Q2, 2020) | (14.2m) |
Market capitalization (8-Feb-2021) | 410.4m |
Closing stock price (8-Feb-2021) | 1.5 |
Cash (30-Jun-2020) | 55.0m |
EV | 356.3m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 2.2m | 4.1m | 6.2m | 9.0m | 12.7m | 10.4m | 7.9m | 8.8m | 10.6m |
R&D expense | 1.2m | 2.6m | 4.7m | 18.6m | 35.5m | 28.5m | 13.3m | 17.6m | 18.2m |
Operating expense total | 3.4m | 6.7m | 10.9m | 27.7m | 48.2m | 39.0m | 21.3m | 26.3m | 28.8m |
EBIT | (3.4m) | (6.7m) | (10.9m) | (27.7m) | (48.2m) | (39.0m) | (21.3m) | (26.3m) | (28.8m) |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 316.0 | 1.1k | 762.7k | 1.0m | 1.1m | 1.3m | 1.1m | 1.6m | 2.0m | 2.2m | 2.9m | 2.9m | 3.0m | 3.3m | 2.3m | 2.1m | 2.1m | 2.0m | 1.9m | 1.8m | 2.1m | 2.3m | 2.4m | 2.4m | 2.8m | 2.6m | 3.6m |
R&D expense | 397.6k | 827.8k | 658.1k | 740.6k | 944.0k | 3.6m | 4.1m | 5.2m | 6.8m | 8.9m | 10.3m | 10.7m | 7.5m | 5.5m | 3.0m | 2.8m | 3.9m | 5.2m | 4.1m | 3.3m | 3.9m | 3.6m | 5.1m | 4.7m | 10.6m | ||
Operating expense total | 316.0 | 1.1k | 1.2m | 1.9m | 1.7m | 2.0m | 2.1m | 5.2m | 6.0m | 7.4m | 9.7m | 11.8m | 13.3m | 14.0m | 9.8m | 7.6m | 5.1m | 4.8m | 5.8m | 7.0m | 6.1m | 5.5m | 6.3m | 5.9m | 7.9m | 7.3m | 14.2m |
Depreciation and amortization | 5.0k |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 747.0 | 205.0 | 2.5m | 1.3m | 35.7k | 423.7k | 68.0k | 7.4m | 49.5m | 43.9m | 46.2m | 58.2m | 48.7m | 33.0m | 8.4m | 14.9m | 15.6m | 19.9m | 34.4m | 29.3m | 19.3m | 16.7m | 14.7m | 16.4m | 12.2m | 10.0m | 30.7m | 55.0m |
Prepaid Expenses | 64.0k | 74.5k | 43.1k | 67.7k | 46.4k | 46.4k | 554.0k | 946.0k | 699.0k | 1.8m | 1.6m | 2.1m | 3.2m | 2.4m | 2.5m | 1.0m | 1.1m | 896.0k | 1.4m | 1.4m | 1.1m | 2.7m | 2.0m | 1.5m | 2.7m | 2.6m | ||
Current Assets | 2.6m | 1.4m | 78.7k | 491.4k | 114.4k | 7.5m | 50.1m | 44.8m | 46.9m | 60.0m | 50.3m | 57.2m | 30.7m | 33.7m | 29.2m | 23.4m | 35.5m | 30.2m | 20.7m | 18.2m | 15.9m | 19.2m | 14.2m | 11.6m | 33.4m | 57.6m | ||
PP&E | 23.2k | 53.2k | 51.0k | 42.8k | 38.8k | 42.8k | 43.0k | 71.0k | 224.0k | 306.0k | 316.0k | 327.0k | 383.0k | 349.0k | 315.0k | 132.0k | 118.0k | 102.0k | 78.0k | 65.0k | 55.0k | 41.0k | 36.0k | 34.0k | 28.0k | 37.0k |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (3.5m) | (9.4m) | (10.9m) | (27.6m) | (48.1m) | (38.8m) | (21.1m) | (26.1m) | (28.6m) |
Depreciation and Amortization | 9.3k | 14.3k | 17.0k | 36.0k | 161.0k | 339.0k | 70.0k | 54.0k | 26.0k |
Accounts Payable | 377.5k | 130.6k | (60.0k) | 728.0k | 1.6m | (2.2m) | 424.0k | 106.0k | 1.7m |
Cash From Operating Activities | (2.6m) | (5.7m) | (8.5m) | (22.8m) | (42.5m) | (37.3m) | (19.1m) | (24.0m) | (26.7m) |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (1.5k) | (2.3k) | (2.0m) | (5.1m) | (6.8m) | (2.0m) | (4.1m) | (7.2m) | (5.2m) | (11.2m) | (18.6m) | (9.7m) | (21.4m) | (34.7m) | (14.0m) | (23.8m) | (31.4m) | (5.1m) | (9.8m) | (15.6m) | (6.9m) | (13.0m) | (18.5m) | (6.2m) | (12.1m) | (19.9m) | (7.3m) | (21.5m) |
Depreciation and Amortization | 2.4k | 6.1k | 10.2k | 4.1k | 8.1k | 12.2k | 4.0k | 9.0k | 15.0k | 22.0k | 45.0k | 90.0k | 57.0k | 113.0k | 163.0k | 24.0k | 34.0k | 50.0k | 15.0k | 30.0k | 43.0k | 9.0k | 16.0k | 21.0k | 6.0k | 12.0k | ||
Accounts Payable | (512.8k) | (208.3k) | 2.2k | 44.3k | 635.4k | 160.0k | 635.0k | 754.0k | 1.7m | 502.0k | 1.3m | 948.0k | (986.0k) | (1.1m) | (2.1m) | (31.0k) | 307.0k | 490.0k | (32.0k) | 342.0k | (249.0k) | (270.0k) | (358.0k) | (285.0k) | (1.7m) | 118.0k | ||
Cash From Operating Activities | (1.8m) | (2.9m) | (4.2m) | (1.4m) | (2.1m) | (5.0m) | (4.1m) | (9.8m) | (14.6m) | (9.1m) | (18.3m) | (30.6m) | (15.5m) | (23.5m) | (31.9m) | (4.8m) | (9.2m) | (14.2m) | (6.8m) | (12.3m) | (17.1m) | (8.6m) | (13.4m) | (20.0m) | (9.3m) | (19.4m) |
USD | Q2, 2011 |
---|---|
Financial Leverage | -0.1 x |
When was Tonix Pharmaceuticals founded?
Tonix Pharmaceuticals was founded in 2007.
Who are Tonix Pharmaceuticals key executives?
Tonix Pharmaceuticals's key executives are Seth Lederman, Jessica Edgar Morris and Margaret Smith Bell.
How many employees does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 16 employees.
Who are Tonix Pharmaceuticals competitors?
Competitors of Tonix Pharmaceuticals include Savara Pharmaceuticals, ThermoGenesis and Precision Medicine Group.
Where is Tonix Pharmaceuticals headquarters?
Tonix Pharmaceuticals headquarters is located at 509 Madison Ave, New York.
Where are Tonix Pharmaceuticals offices?
Tonix Pharmaceuticals has offices in New York, San Diego, Montréal and Dublin.
How many offices does Tonix Pharmaceuticals have?
Tonix Pharmaceuticals has 4 offices.
Receive alerts for 300+ data fields across thousands of companies